SEC Form 10-Q filed by ImageneBio Inc.
$IMA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/25/2025 | $2.00 | Underperform | Wedbush |
| 10/24/2025 | $30.00 | Outperform | Leerink Partners |
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene" or the "Company")), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions, providing strategic counsel as the Company advances its lead candidate, IMG-007. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, PhD, Chief Executive Officer of Imagene. "Matt’s experience building a legal function inside a clinical-
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings. Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds of approximately $30 million led by new investor, Coastlands Capital, with participation from Trails Edge Capital Partners and existing investors Omega Funds and OrbiMed, among others. The financing extends the Company's cash runway into the first quarter of 2028 and enables
424B3 - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00
Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene" or the "Company")), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions, providing strategic counsel as the Company advances its lead candidate, IMG-007. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, PhD, Chief Executive Officer of Imagene. "Matt’s experience building a legal function inside a clinical-
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo